Here’s a bold statement: despite decades of research, countless neurological and psychiatric conditions still lack effective treatments that work for everyone. And this is the part most people miss—while it’s true that many of today’s medications stem from traditional remedies or serendipitous discoveries, basic neuroscience has quietly paved the way for groundbreaking drugs that wouldn’t exist otherwise. But here’s where it gets controversial: is basic research truly worth the investment when its impact on drug development seems slow and uncertain? Let’s dive in.
Consider this: medications like zuranolone for postpartum depression, suzetrigine for pain, and gepants for migraines were not stumbled upon by chance. They emerged from years of meticulous lab research, proving that neuroscience can indeed deliver life-changing treatments. But here’s the catch—these successes are often overshadowed by the slow pace of translation from lab to clinic, leaving many to question the value of basic research. Yet, acknowledging these victories is more critical than ever, especially as public funding for neuroscience faces growing cuts and restrictions.
Take zuranolone, for example. Its development began with a simple observation: allopregnanolone, a naturally occurring steroid, plays a key role in regulating brain excitability. Researchers noticed that its levels plummet just before childbirth, sparking a bold hypothesis—could this crash trigger postpartum depression? Clinical trials confirmed the theory, leading to the FDA’s approval of brexanolone (Zulresso) in 2019 and its oral counterpart, zuranolone (Zurzuvae), two years later. This wasn’t luck; it was the result of decades of research.
Similarly, suzetrigine, a non-opioid pain drug, emerged from a 1996 study identifying Nav1.8, a unique sodium channel in sensory neurons. By targeting this channel, scientists developed a pain treatment without the addictive risks of opioids. And then there’s the story of CGRP, a peptide discovered in the 1990s, which inspired a new class of migraine therapies like ubrogepant (Ubrelvy), offering hope to those who don’t respond to traditional treatments.
But here’s where it gets controversial: if basic neuroscience has such potential, why aren’t there more success stories? The answer lies in the complexities of drug development—skyrocketing costs, flawed trial designs, and unforeseen side effects often derail progress. Yet, by studying past successes, we can improve translation. For instance, focusing on well-defined conditions like postpartum depression, rather than broad categories like general depression, has yielded faster results. And while animal models are useful, simple measurements—like allopregnanolone levels during pregnancy—can sometimes provide the most powerful insights.
The recent breakthroughs also highlight a critical truth: translation takes time. Many of today’s treatments began with discoveries made in the 1980s and 1990s, only becoming available to patients in the last few years. With the pace of discovery accelerating, we’re on the cusp of more transformative medicines—but only if we sustain public investment in basic research.
Now, here’s the thought-provoking question: Do you believe basic neuroscience deserves continued funding, even if its impact isn’t immediate? Or should resources be redirected to more ‘practical’ areas of research? Share your thoughts in the comments—let’s spark a conversation that could shape the future of medicine.
